Trial Condition(s):

Pulmonary hypertension

Observational study on residual disease in chronic thromboembolic pulmonary hypertension following pulmonary endarterectomy

Bayer Identifier:

20565 Identifier:

Not Available

EudraCT Number:

Not Available

EU CT Number:

Not Available

Study Completed

Trial Purpose

Chronic thromboembolic pulmonary hypertension (CTEPH) is a form of pulmonary hypertension caused by obstruction of the pulmonary vasculature by thromboembolic material and is potentially curable by pulmonary endarterectomy (PEA) surgery. However, in some cases patients may experience recurrent or persistent (residual) disease following PEA.

The proposed study will describe the rates of symptoms and diagnostic procedural claims related to residual disease in CTEPH patients over a two year period following PEA.

The results may help to identify potential gaps in care and to raise awareness of the need to follow-up and screen at risk post-PEA patients for residual disease.

Inclusion Criteria
- Adults patients ≥ 18 years of age on the index date
- One claim of pulmonary endarterectomy (PEA) following a claim of pulmonary hypertension (PH) or chronic thromboembolic pulmonary hypertension (CTEPH)
- ≥ 730 days continuous enrollment post-PEA
Exclusion Criteria
- Patients under the age of 18
- Patients with < 730 days of continuous enrollment following the index date

Trial Summary

Enrollment Goal
Trial Dates
Could I receive a placebo?
No Drug
Accepts Healthy Volunteers

Where to Participate


Multipal locations

Cleveland, United States, 44195

Trial Design